US 12,440,465 B2
Nutritional compositions and associated methods
Angela Mastaloudis, Holladay, UT (US); Steven M. Wood, Santaquin, UT (US); Mark Bartlett, Orem, UT (US); and Shelly Hester, Provo, UT (US)
Assigned to NSE Products, Inc., Provo, UT (US)
Filed by NSE Products, Inc., Provo, UT (US)
Filed on Aug. 31, 2016, as Appl. No. 15/253,710.
Prior Publication US 2018/0055802 A1, Mar. 1, 2018
Int. Cl. A61K 31/202 (2006.01); A61K 31/015 (2006.01); A61K 31/05 (2006.01); A61K 31/122 (2006.01); A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61K 31/385 (2006.01); A61K 31/593 (2006.01); A61K 31/7048 (2006.01); A61K 36/53 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/202 (2013.01) [A61K 31/015 (2013.01); A61K 31/05 (2013.01); A61K 31/122 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/385 (2013.01); A61K 31/593 (2013.01); A61K 31/7048 (2013.01); A61K 36/53 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. An oral formulation, comprising:
from 8 wt % to 48 wt % of polyunsaturated fatty acids including EPA and DHA,
additional polyunsaturated fatty acids including alpha lipoic acid (ALA),
from 0.1 wt % to 4 wt % stilbenoid including a member selected from the group consisting of resveratrol, vitisin A, pterostilbene, piceatannolin, astringin, piceid, and combinations thereof,
from 3 wt % to 15 wt % flavonoid including a member selected from the group consisting of flavonol, flavanone, anthocyanin, quercetin, and combinations thereof,
from 0.005 wt % to 2 wt % carotenoid,
from 0.1 wt % to 5 wt % D-limonene, and
from 100 IU to 2,000 IU vitamin D,
wherein the polyunsaturated fatty acids including EPA and DHA, the stilbenoid, the flavonoid, and the vitamin D are present in an amount and at a weight ratio that causes the oral formulation to induce a gene expression profile containing at least 20% of the genes in a gene expression profile of caloric restriction in a muscle tissue of a subject and protects skin cells against ultraviolet radiation when administered to the subject in a therapeutically effective amount, and
wherein the stilbenoid and the polyunsaturated fatty acids including EPA and DHA are present in the oral formulation at a weight ratio of from 1:50 to 1:20 of the stilbenoid to the polyunsaturated fatty acids including EPA and DHA.